Drug Eluting Balloon for Treatment of Unstable Angina

NCT ID: NCT02760732

Last Updated: 2017-11-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-11-30

Study Completion Date

2018-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study was to investigate the effect and safety of drug eluting balloon combined for treatment of unstable angina.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with unstable angina were randomized to drug eluting stent only or drug eluting balloon group. Angiographic follow-up was performed after 12 months. The primary endpoints were late lumen loss (LLL) and the secondary endpoints were target lesion revascularization (TLR),and the major adverse cardiovascular events (MACE) .

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Angina, Unstable

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

drug eluting balloon group

patients with unstable angina were randomised to drug eluting balloon group for percutaneous transluminal coronary angioplasty with a strategy of cutting balloon(Flextome Cutting Balloon, Boston Scientific Corporation, US) pre-dilation first and then drug eluting balloon(Sequent please; B. Braun, Melsungen, Germany) .

Group Type EXPERIMENTAL

drug eluting balloon; cutting balloon

Intervention Type DEVICE

Patients eligible for inclusion criteria were randomised to study group for percutaneous transluminal coronary angioplasty with a strategy of cutting balloon pre-dilation first and then drug eluting balloon.

drug eluting stent group

patients with unstable angina were randomised to this group for drug eluting stent (YINYI® Polymer-free Drug-coated (Paclitaxel) Coronary Stent System, Liaoning Biomedical Materials R\&D Center Co., Ltd. China) implantation.

Group Type EXPERIMENTAL

drug eluting stent

Intervention Type DEVICE

with a strategy of drug-eluting stent implantation alone for de novo coronary artery lesions.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

drug eluting balloon; cutting balloon

Patients eligible for inclusion criteria were randomised to study group for percutaneous transluminal coronary angioplasty with a strategy of cutting balloon pre-dilation first and then drug eluting balloon.

Intervention Type DEVICE

drug eluting stent

with a strategy of drug-eluting stent implantation alone for de novo coronary artery lesions.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Sequent please; B. Braun; Flextome Cutting Balloon, Boston Scientific YINYI®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients \> 18, \< 80 years old, with unstable angina
* Single-vessel or double-vessel disease
* Length of target lesion \< 25mm
* Diameter of target vessel \>2.5mm, \< 3.5mm

Exclusion Criteria

* Left main disease
* Chronic total occlusion
* Severe Tortuosity
* Heavy calcification
* Severe liver failure, moderate or severe kidney failure
* Malignant disease
* Active infectious disease
* Pregnancy or breastfeeding
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Yun Dai Chen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Yun Dai Chen

MD

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

CHEN YUN DAI, MD

Role: PRINCIPAL_INVESTIGATOR

The General Hospital of PLA

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The General Hospital of PLA

Beijing, Beijing Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

LI BO, MD

Role: CONTACT

Phone: +8601055499309

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

LI BO, MD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Li B, Ding Y, Tian F, Chen W, Han T, Chen Y. Assessment of a Drug-Eluting Balloon for the Treatment of de novo Coronary Lesions Guided by Optical Coherence Tomography: Study Protocol for a Randomized Controlled Trial. Cardiology. 2017;136(4):252-257. doi: 10.1159/000452125. Epub 2016 Nov 16.

Reference Type DERIVED
PMID: 27846629 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

301_xnk1

Identifier Type: -

Identifier Source: org_study_id